"line\\\">Common Adverse Reactions</span></p><p><a href=\\\"#t1\\\">Table 1</a> shows common adverse reactions, not including hypoglycemia, associated with the use of MOUNJARO in the pool of placebo-controlled trials. These adverse reactions occurred more commonly on MOUNJARO than on placebo and occurred in at least 5% of patients treated with MOUNJARO.</p><a name=\\\"t1\\\"></a><table width=\\\"100%\\\"><caption><span>Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials Reported in ≥5% of MOUNJARO-treated Adult Patients with Type 2 Diabetes Mellitus</span></caption><col align=\\\"left\\\" width=\\\"24.040%\\\"/><col align=\\\"left\\\" width=\\\"19.240%\\\"/><col align=\\\"left\\\" width=\\\"18.260%\\\"/><col align=\\\"left\\\" width=\\\"20.200%\\\"/><col align=\\\"left\\\" width=\\\"18.260%\\\"/><tfoot><tr class=\\\"First Last\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">Note: Percentages reflect the number of patients who reported at least 1 occurrence of the adverse reaction.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Adverse Reaction</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo<br/>(N=235)<br/>%</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO <br/>5 mg<br/>(N=237)<br/>%</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO <br/>10 mg<br/>(N=240)<br/>%</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO <br/>15 mg<br/>(N=241)<br/>%</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Nausea</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">12</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">15</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">18</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Diarrhea</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">12</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">13</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">17</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Decreased Appetite</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">10</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">11</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Vomiting</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">9</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Constipation</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Dyspepsia</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">5</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">Abdominal Pain</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">5</td></tr></tbody></table><p>In the pool of seven clinical trials, the types and frequency of common adverse reactions, not including hypoglycemia, were similar to those listed in <a href=\\\"#t1\\\">Table 1</a>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s23\\\"></a><a name=\\\"section-6.1.4\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Gastrointestinal Adverse Reactions</span></p><p>In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving MOUNJARO than placebo (placebo 20.4%, MOUNJARO 5 mg 37.1%, MOUNJARO 10 mg 39.6%, MOUNJARO 15 mg 43.6%). More patients receiving MOUNJARO 5 mg (3.0%), MOUNJARO 10 mg (5.4%), and MOUNJARO 15 mg (6.6%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation and decreased over time.</p><p>The following gastrointestinal adverse reactions were reported more frequently in MOUNJARO-treated patients than placebo-treated patients (frequencies listed, respectively, as: placebo; 5 mg; 10 mg; 15 mg): eructation (0.4%, 3.0%, 2.5%, 3.3%), flatulence (0%, 1.3%, 2.5%, 2.9%), gastroesophageal reflux disease (0.4%, 1.7%, 2.5%, 1.7%), abdominal distension (0.4%, 0.4%, 2.9%, 0.8%).</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s24\\\"></a><a name=\\\"section-6.1.5\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Other Adverse Reactions</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s25\\\"></a><a name=\\\"section-6.1.5.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Hypoglycemia</span></p><p><a href=\\\"#t2\\\">Table 2</a> summarizes the incidence of hypoglycemic events in the placebo-controlled trials.</p><a name=\\\"t2\\\"></a><table width=\\\"100%\\\"><caption><span>Table 2: Hypoglycemia Adverse Reactions in Placebo-Controlled Trials in Adult Patients with Type 2 Diabetes Mellitus</span></caption><col align=\\\"left\\\" width=\\\"32.320%\\\"/><col align=\\\"left\\\" width=\\\"16.660%\\\"/><col align=\\\"left\\\" width=\\\"16.680%\\\"/><col align=\\\"left\\\" width=\\\"16.680%\\\"/><col align=\\\"left\\\" width=\\\"17.660%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">* Reflects the study treatment period. Data include events occurring during 4 weeks of treatment-free safety follow up. Events after introduction of a new glucose-lowering treatment are excluded.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\">** Episodes requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo<br/></span><br/><span class=\\\"Bold\\\">%</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO <br/>5 mg</span><br/><span class=\\\"Bold\\\">%</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO <br/>10 mg</span><br/><span class=\\\"Bold\\\">%</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO <br/>15 mg</span><br/><span class=\\\"Bold\\\">%</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Monotherapy</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">      (40 weeks)*</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">N=115</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">N=121</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">N=119</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">N=120</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Blood glucose &lt;54 mg/dL</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Severe hypoglycemia**</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Add-on to Basal Insulin with or without Metformin</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">      (40 weeks)*</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">N=120</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">N=116</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">N=119</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">N=120</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Blood glucose &lt;54 mg/dL</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">13</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">16</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">19</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">14</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Severe hypoglycemia**</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1</td></tr></tbody></table><p>Hypoglycemia was more frequent when MOUNJARO was used in combination with a sulfonylurea <span class=\\\"Italics\\\">[see Clinical Studies (<a href=\\\"#s73\\\">14</a>)]</span>. In a clinical trial up to 104 weeks of treatment, when administered with a sulfonylurea, hypoglycemia (glucose level &lt;54 mg/dL) occurred in 13.8%, 9.9%, and 12.8%, and severe hypoglycemia occurred in 0.5%, 0%, and 0.6% of patients treated with MOUNJARO 5 mg, 10 mg, and 15 mg, respectively.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s26\\\"></a><a name=\\\"section-6.1.5.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Heart Rate Increase</span></p><p>In the pool of placebo-controlled trials, treatment with MOUNJARO resulted in a mean increase in heart rate of 2 to 4 beats per minute compared to a mean increase of 1 beat per minute in placebo-treated patients. Episodes of sinus tachycardia, associated with a concomitant increase from baseline in heart rate of ≥15 beats per minute, also were reported in 4.3%, 4.6%, 5.9% and 10% of subjects treated with placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. For patients enrolled in Japan, these episodes were reported in 7% (3/43), 7.1% (3/42), 9.3% (4/43), and 23% (10/43) of patients treated with placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. The clinical relevance of heart rate increases is uncertain.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s27\\\"></a><a name=\\\"section-6.1.5.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Hypersensitivity Reactions</span></p><p>Hypersensitivity reactions have been reported with MOUNJARO in the pool of placebo-controlled trials, sometimes severe (e.g., urticaria and eczema); hypersensitivity reactions were reported in 3.2% of MOUNJARO-treated patients compared to 1.7% of placebo-treated patients.</p><p>In the pool of seven clinical trials<span class=\\\"Italics\\\">,</span> hypersensitivity reactions occurred in 106/2,570 (4.1%) of MOUNJARO-treated patients with anti-tirzepatide antibodies and in 73/2,455 (3.0%) of MOUNJARO-treated patients who did not develop anti-tirzepatide antibodies <span class=\\\"Italics\\\">[see Clinical Pharmacology (<a href=\\\"#s70\\\">12.6</a>)].</span></p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s28\\\"></a><a name=\\\"section-6.1.5.4\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Injection Site Reactions</span></p><p>In the pool of placebo-controlled trials, injection site reactions were reported in 3.2% of MOUNJARO-treated patients compared to 0.4% of placebo-treated patients.</p><p>In the pool of seven clinical trials, injection site reactions occurred in 119/2,570 (4.6%) of MOUNJARO-treated patients with anti-tirzepatide antibodies and in 18/2,455 (0.7%) of MOUNJARO-treated patients who did not develop anti-tirzepatide antibodies <span class=\\\"Italics\\\">[see Clinical Pharmacology (<a href=\\\"#s70\\\">12.6</a>)].</span></p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s29\\\"></a><a name=\\\"section-6.1.5.5\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Acute Gallbladder Disease</span></p><p>In the pool of placebo-controlled clinical trials, acute gallbladder disease (cholelithiasis, biliary colic and cholecystectomy) was reported by 0.6% of MOUNJARO-treated patients and 0% of placebo-treated patients.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s29a\\\"></a><a name=\\\"section-6.1.5.6\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Dysesthesia</span></p><p>In the pool of placebo-controlled clinical trials, dysesthesia was reported by 0.4%, 0.4%, and 0.4% of patients treated with MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. No events were reported by patients receiving placebo.  </p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s29b\\\"></a><a name=\\\"section-6.1.5.7\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Dysgeusia</span></p><p>In the pool of placebo-controlled clinical trials, dysgeusia was reported by 0.1% of MOUNJARO-treated patients and 0% of placebo-treated patients.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s30\\\"></a><a name=\\\"section-6.1.6\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Laboratory Abnormalities</span></p><p><span class=\\\"Italics\\\">Amylase and Lipase Increase</span></p><p>In the pool of placebo-controlled clinical trials, treatment with MOUNJARO resulted in mean increases from baseline in serum pancreatic amylase concentrations of 33% to 38% and serum lipase concentrations of 31% to 42%. Placebo-treated patients had a mean increase from baseline in pancreatic amylase of 4% and no changes were observed in lipase. The clinical significance of elevations in lipase or amylase with MOUNJARO is unknown in the absence of other signs and symptoms of pancreatitis.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"90375-7\\\"><a name=\\\"s31\\\"></a><a name=\\\"section-6.2\\\"></a><p></p><h2>6.2 Postmarketing Experience</h2><p class=\\\"First\\\">The following adverse reactions have been reported during post-approval use of MOUNJARO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p><span class=\\\"Italics\\\">Hypersensitivity</span>: anaphylaxis, angioedema</p><p><span class=\\\"Italics\\\">Gastrointestinal</span>: ileus</p><p><span class=\\\"Italics\\\">Pulmonary</span>: Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation.</p></div></section>\",\n            \"drugInteractions\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34073-7\\\"><a name=\\\"s32\\\"></a><a name=\\\"section-7\\\"></a><p></p><h1>7 DRUG INTERACTIONS</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s33\\\"></a><a name=\\\"section-7.1\\\"></a><p></p><h2>7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin</h2><p class=\\\"First\\\">When initiating MOUNJARO, consider reducing the dose of concomitantly administered insulin secretagogues (e.g., sulfonylureas) or insulin to reduce the risk of hypoglycemia <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s12\\\">5.3</a>)].</span></p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s34\\\"></a><a name=\\\"section-7.2\\\"></a><p></p><h2>7.2 Oral Medications</h2><p class=\\\"First\\\">MOUNJARO delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with MOUNJARO.</p><p>Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with MOUNJARO.</p><p>Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO. Hormonal contraceptives that are not administered orally should not be affected <span class=\\\"Italics\\\">[see Use in Specific Populations (<a href=\\\"#s44\\\">8.3</a>) and Clinical Pharmacology (<a href=\\\"#s54\\\">12.2</a>, <a href=\\\"#s59\\\">12.3</a>)].</span></p></div></section>\",\n            \"clinicalPharmacology\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34090-1\\\"><a name=\\\"s52\\\"></a><a name=\\\"section-11\\\"></a><p></p><h1>12 CLINICAL PHARMACOLOGY</h1><div class=\\\"Section\\\" data-sectioncode=\\\"43679-0\\\"><a name=\\\"s53\\\"></a><a name=\\\"section-11.1\\\"></a><p></p><h2>12.1 Mechanism of Action</h2><p class=\\\"First\\\">Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It is an amino-acid sequence including a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1.</p><p>Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"43681-6\\\"><a name=\\\"s54\\\"></a><a name=\\\"section-11.2\\\"></a><p></p><h2>12.2 Pharmacodynamics</h2><p class=\\\"First\\\">Tirzepatide lowers fasting and postprandial glucose concentration, decreases food intake, and reduces body weight in patients with type 2 diabetes mellitus.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s55\\\"></a><a name=\\\"section-11.2.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">First and Second-Phase Insulin Secretion</span></p><p>Tirzepatide enhances the first- and second-phase insulin secretion. (<a href=\\\"#fig1\\\">Figure 1</a>)<br/><br/></p><p class=\\\"MultiMediaCaption\\\"><a name=\\\"fig1\\\"></a><span class=\\\"Bold\\\">Figure 1: Mean insulin concentration at 0-120 minutes during hyperglycemic clamp at baseline and Week 28</span></p><div class=\\\"Figure\\\"><a name=\\\"f02\\\"></a><img alt=\\\"Figure 1\\n\\\" src=\\\"moun-uspi-f1-v1.jpg\\\"/></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s56\\\"></a><a name=\\\"section-11.2.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Insulin Sensitivity</span></p><p>Tirzepatide increases insulin sensitivity, as demonstrated in a hyperinsulinemic euglycemic clamp study after 28 weeks of treatment.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s57\\\"></a><a name=\\\"section-11.2.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Glucagon Secretion</span></p><p>Tirzepatide reduces fasting and postprandial glucagon concentrations. Tirzepatide 15 mg reduced fasting glucagon concentration by 28% and glucagon AUC after a mixed meal by 43%, compared with no change for placebo after 28 weeks of treatment.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s58\\\"></a><a name=\\\"section-11.2.4\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Gastric Emptying</span></p><p>Tirzepatide delays gastric emptying. The delay is largest after the first dose and this effect diminishes over time. Tirzepatide slows post-meal glucose absorption, reducing postprandial glucose.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"43682-4\\\"><a name=\\\"s59\\\"></a><a name=\\\"section-11.3\\\"></a><p></p><h2>12.3 Pharmacokinetics</h2><p class=\\\"First\\\">The pharmacokinetics of tirzepatide is similar between healthy subjects and patients with type 2 diabetes mellitus. Steady-state plasma tirzepatide concentrations were achieved following 4 weeks of once weekly administration. Tirzepatide exposure increases in a dose-proportional manner.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s60\\\"></a><a name=\\\"section-11.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Absorption</span></p><p>Following subcutaneous administration, the time to maximum plasma concentration of tirzepatide ranges from 8 to 72 hours. The mean absolute bioavailability of tirzepatide following subcutaneous administration is 80%. Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s61\\\"></a><a name=\\\"section-11.3.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Distribution</span></p><p>The mean apparent steady-state volume of distribution of tirzepatide following subcutaneous administration in patients with type 2 diabetes mellitus is approximately 10.3 L. Tirzepatide is highly bound to plasma albumin (99%).</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s62\\\"></a><a name=\\\"section-11.3.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Elimination</span></p><p>The apparent population mean clearance of tirzepatide is 0.061 L/h with an elimination half-life of approximately 5 days, enabling once-weekly dosing.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s63\\\"></a><a name=\\\"section-11.3.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Metabolism</span></p><p>Tirzepatide is metabolized by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid and amide hydrolysis.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s64\\\"></a><a name=\\\"section-11.3.3.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Excretion</span></p><p>The primary excretion routes of tirzepatide metabolites are via urine and feces. Intact tirzepatide is not observed in urine or feces.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s65\\\"></a><a name=\\\"section-11.3.4\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Specific Populations</span></p><p>The intrinsic factors of age, gender, race, ethnicity, or body weight do not have a clinically relevant effect on the PK of tirzepatide.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s66\\\"></a><a name=\\\"section-11.3.4.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Patients with Renal Impairment</span></p><p>Renal impairment does not impact the pharmacokinetics of tirzepatide. The pharmacokinetics of tirzepatide after a single 5 mg dose was evaluated in patients with different degrees of renal impairment (mild, moderate, severe, ESRD) compared with subjects with normal renal function. This was also shown for patients with both type 2 diabetes mellitus and renal impairment based on data from clinical studies <span class=\\\"Italics\\\">[see Use in Specific Populations (<a href=\\\"#s48\\\">8.6</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s67\\\"></a><a name=\\\"section-11.3.4.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Patients with Hepatic Impairment</span></p><p>Hepatic impairment does not impact the pharmacokinetics of tirzepatide. The pharmacokinetics of tirzepatide after a single 5 mg dose was evaluated in patients with different degrees of hepatic impairment (mild, moderate, severe) compared with subjects with normal hepatic function <span class=\\\"Italics\\\">[see Use in Specific Populations (<a href=\\\"#s49\\\">8.7</a>)]</span>.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s68\\\"></a><a name=\\\"section-11.3.5\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Drug Interactions Studies</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s69\\\"></a><a name=\\\"section-11.3.5.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Potential for Tirzepatide to Influence the Pharmacokinetics of Other Drugs</span></p><p>In vitro studies have shown low potential for tirzepatide to inhibit or induce CYP enzymes, and to inhibit drug transporters.</p><p>MOUNJARO delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications <span class=\\\"Italics\\\">[see Drug Interactions (<a href=\\\"#s34\\\">7.2</a>)]</span>.</p><p>The impact of tirzepatide on gastric emptying was greatest after a single dose of 5 mg and diminished after subsequent doses.</p><p>Following a first dose of tirzepatide 5 mg, acetaminophen maximum concentration (C<span class=\\\"Sub\\\">max</span>) was reduced by 50%, and the median peak plasma concentration (t<span class=\\\"Sub\\\">max</span>) occurred 1 hour later. After coadministration at week 4, there was no meaningful impact on acetaminophen C<span class=\\\"Sub\\\">max</span> and t<span class=\\\"Sub\\\">max</span>. Overall acetaminophen exposure (AUC<span class=\\\"Sub\\\">0-24hr</span>) was not influenced.</p><p>Following administration of a combined oral contraceptive (0.035 mg ethinyl estradiol and 0.25 mg norgestimate) in the presence of a single dose of tirzepatide 5 mg, mean C<span class=\\\"Sub\\\">max</span> of ethinyl estradiol, norgestimate, and norelgestromin was reduced by 59%,66%, and 55%, while mean AUC was reduced by 20%, 21%, and 23%, respectively. A delay in t<span class=\\\"Sub\\\">max</span> of 2.5 to 4.5 hours was observed.</p></div></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s70\\\"></a><a name=\\\"section-11.4\\\"></a><p></p><h2>12.6 Immunogenicity</h2><p class=\\\"First\\\">The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the trials described below with the incidence of anti-drug antibodies in other trials.</p><p>During the 40- to 104-week treatment periods with ADA sampling conducted up to 44 to 108 weeks in seven clinical trials in adults with type 2 diabetes mellitus <span class=\\\"Italics\\\">[see Clinical Studies (<a href=\\\"#s73\\\">14</a>)],</span> 51% (2,570/5,025) of MOUNJARO-treated patients developed anti-tirzepatide antibodies. In these trials, anti-tirzepatide antibody formation in 34% and 14% of MOUNJARO-treated patients showed cross-reactivity to native GIP or native GLP-1, respectively.</p><p>Of the 2,570 MOUNJARO-treated patients who developed anti-tirzepatide antibodies during the treatment periods in these seven trials, 2% and 2% developed neutralizing antibodies against tirzepatide activity on the GIP or GLP-1 receptors, respectively, and 0.9% and 0.4% developed neutralizing antibodies against native GIP or GLP-1, respectively.</p><p>There was no identified clinically significant effect of anti-tirzepatide antibodies on pharmacokinetics or effectiveness of MOUNJARO. More MOUNJARO-treated patients who developed anti-tirzepatide antibodies experienced hypersensitivity reactions or injection site reactions than those who did not develop these antibodies <span class=\\\"Italics\\\">[see Adverse Reactions (<a href=\\\"#s19\\\">6.1</a>)].</span></p></div></section>\",\n            \"clinicalStudies\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34092-7\\\"><a name=\\\"s73\\\"></a><a name=\\\"section-13\\\"></a><p></p><h1>14 CLINICAL STUDIES</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s74\\\"></a><a name=\\\"section-13.1\\\"></a><p></p><h2>14.1 Overview of Clinical Studies</h2><p class=\\\"First\\\">The effectiveness of MOUNJARO as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus was established in five trials. In these trials, MOUNJARO was studied as monotherapy (SURPASS-1); as an add-on to metformin, sulfonylureas, and/or sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors) (SURPASS-2, -3, and -4); and in combination with basal insulin with or without metformin (SURPASS-5). In these trials, MOUNJARO (5 mg, 10 mg, and 15 mg given subcutaneously once weekly) was compared with placebo, semaglutide 1 mg, insulin degludec, and/or insulin glargine.</p><p>In adult patients with type 2 diabetes mellitus, treatment with MOUNJARO produced a statistically significant reduction from baseline in HbA1c compared to placebo. The effectiveness of MOUNJARO was not impacted by age, gender, race, ethnicity, region, or by baseline BMI, HbA1c, diabetes duration, or renal function.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s75\\\"></a><a name=\\\"section-13.2\\\"></a><p></p><h2>14.2 Monotherapy Use of MOUNJARO in Adult Patients with Type 2 Diabetes Mellitus</h2><p class=\\\"First\\\">SURPASS-1 (NCT03954834) was a 40-week double-blind trial that randomized 478 adult patients with type 2 diabetes mellitus with inadequate glycemic control with diet and exercise to MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg, or placebo once weekly.</p><p>Patients had a mean age of 54 years, and 52% were men. The mean duration of type 2 diabetes mellitus was 4.7 years, and the mean BMI was 32 kg/m<span class=\\\"Sup\\\">2</span>. Overall, 36% were White, 35% were Asian, 25% were American Indians/Alaska Natives, and 5% were Black or African American; 43% identified as Hispanic or Latino ethnicity.</p><p>Monotherapy with MOUNJARO 5 mg, 10 mg and 15 mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA1c compared with placebo (see <a href=\\\"#t3\\\">Table 3</a>).</p><a name=\\\"t3\\\"></a><table width=\\\"100%\\\"><caption><span>Table 3: Results at Week 40 in a Trial of MOUNJARO as Monotherapy in Adult Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control with Diet and Exercise</span></caption><col align=\\\"left\\\" width=\\\"28.374%\\\"/><col align=\\\"left\\\" width=\\\"18.836%\\\"/><col align=\\\"left\\\" width=\\\"17.596%\\\"/><col align=\\\"left\\\" width=\\\"17.596%\\\"/><col align=\\\"left\\\" width=\\\"17.596%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 25%, 2%, 3%, and 2% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 40 the HbA1c data were missing for 12%, 6%, 7%, and 14% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 40 data were imputed using placebo-based multiple imputation.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> p&lt;0.001 (two-sided) for superiority vs. placebo, adjusted for multiplicity.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">d</span> Analyzed using logistic regression adjusted for baseline value and other stratification factors.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO<br/>5 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO<br/>10 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO<br/>15 mg</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Modified Intent-to-Treat (mITT) Population (N)<span class=\\\"Sup\\\">a</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">113</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">121</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">121</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">120</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">HbA1c (%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline (mean)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">7.9</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Change at Week 40<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.7</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.7</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Difference from placebo<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">--</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.7<span class=\\\"Sup\\\">c</span><br/>(-2.0, -1.4)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.6<span class=\\\"Sup\\\">c</span><br/>(-1.9, -1.3)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.6<span class=\\\"Sup\\\">c</span><br/>(-1.9, -1.3)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Patients (%) achieving HbA1c &lt;7%<span class=\\\"Sup\\\">d</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">23</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">82<span class=\\\"Sup\\\">c</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">85<span class=\\\"Sup\\\">c</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">78<span class=\\\"Sup\\\">c</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Fasting Serum Glucose (mg/dL)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline (mean)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">155</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">154</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">153</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">154</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Change at Week 40<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-40</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-40</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-39</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Difference from <br/>     placebo<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">--</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-43<span class=\\\"Sup\\\">c</span><br/>(-55, -32)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-43<span class=\\\"Sup\\\">c</span><br/>(-55, -32)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-42<span class=\\\"Sup\\\">c</span><br/>(-54, -30)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Body Weight (kg)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline (mean)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">84.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">87.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">86.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">85.5</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Change at Week 40<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-6.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-7.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-7.8</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Difference from <br/>     placebo<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">--</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-5.3<span class=\\\"Sup\\\">c</span><br/>(-6.8, -3.9)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-6.0<span class=\\\"Sup\\\">c</span><br/>(-7.4, -4.6)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-6.8<span class=\\\"Sup\\\">c</span><br/>(-8.3, -5.4)</td></tr></tbody></table></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s76\\\"></a><a name=\\\"section-13.3\\\"></a><p></p><h2>14.3 MOUNJARO Use in Combination with Metformin, Sulfonylureas, and/or SGLT2 Inhibitors in Adult Patients with Type 2 Diabetes Mellitus</h2><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s77\\\"></a><a name=\\\"section-13.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Add-on to metformin</span></p><p>SURPASS-2 (NCT03987919) was a 40-week open-label trial (double-blind with respect to MOUNJARO dose assignment) that randomized 1879 adult patients with type 2 diabetes mellitus with inadequate glycemic control on stable doses of metformin alone to the addition of MOUNJARO 5 mg, MOUNJARO 10 mg, or MOUNJARO 15 mg once weekly or subcutaneous semaglutide 1 mg once weekly.</p><p>Patients had a mean age of 57 years and 47% were men. The mean duration of type 2 diabetes mellitus was 8.6 years, and the mean BMI was 34 kg/m<span class=\\\"Sup\\\">2</span>. Overall, 83% were White, 4% were Black or African American, and 1% were Asian; 70% identified as Hispanic or Latino ethnicity.</p><p>Treatment with MOUNJARO 10 mg and 15 mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA1c compared with semaglutide 1 mg once weekly (see <a href=\\\"#t4\\\">Table 4</a> and <a href=\\\"#fig2\\\">Figure 2</a>).</p><a name=\\\"t4\\\"></a><table width=\\\"100%\\\"><caption><span>Table 4: Results at Week 40 in a Trial of MOUNJARO versus Semaglutide 1 mg in Adult Patients with Type 2 Diabetes Mellitus Added to Metformin</span></caption><col align=\\\"left\\\" width=\\\"43.160%\\\"/><col align=\\\"left\\\" width=\\\"13.700%\\\"/><col align=\\\"left\\\" width=\\\"13.500%\\\"/><col align=\\\"left\\\" width=\\\"14.820%\\\"/><col align=\\\"left\\\" width=\\\"14.820%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 3%, 2%, 1%, and 1% of patients randomized to semaglutide 1 mg, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 40 the HbA1c endpoint was missing for 5%, 4%, 5%, and 5% of patients randomized to semaglutide 1 mg, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 40 data were imputed using multiple imputation with retrieved dropout.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> p&lt;0.05 (two-sided) for superiority vs. semaglutide, adjusted for multiplicity.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">d</span> p&lt;0.001 (two-sided) for superiority vs. semaglutide, adjusted for multiplicity.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">e</span> Analyzed using logistic regression adjusted for baseline value and other stratification factors.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">f</span> p&lt;0.01 (two-sided) for superiority vs. semaglutide, adjusted for multiplicity.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Semaglutide <br/>1 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO<br/>5 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO<br/>10 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO<br/>15 mg</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Modified Intent-to-Treat (mITT) Population (N)<span class=\\\"Bold\\\"><span class=\\\"Sup\\\">a</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">468</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">470</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">469</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">469</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">HbA1c (%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline (mean)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.3</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Change at Week 40<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.3</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Difference from semaglutide<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">--</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.2<span class=\\\"Sup\\\">c</span><br/>(-0.3, -0.0)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.4<span class=\\\"Sup\\\">d</span><br/>(-0.5, -0.3)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.5<span class=\\\"Sup\\\">d</span><br/>(-0.6, -0.3)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Patients (%) achieving HbA1c &lt;7%<span class=\\\"Sup\\\">e</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">79</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">82</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">86<span class=\\\"Sup\\\">f</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">86<span class=\\\"Sup\\\">f</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Fasting Serum Glucose (mg/dL)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline (mean)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">171</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">174</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">174</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">172</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Change at Week 40<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-49</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-55</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-59</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-60</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Body Weight (kg)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline (mean)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">93.7</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">92.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">94.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">93.8</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Change at Week 40<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-5.7</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-7.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-9.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-11.2</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Difference from semaglutide<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">--</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.9<span class=\\\"Sup\\\">c</span><br/>(-2.8, -1.0)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-3.6<span class=\\\"Sup\\\">d</span><br/>(-4.5, -2.7)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-5.5<span class=\\\"Sup\\\">d</span><br/>(-6.4, -4.6)</td></tr></tbody></table><p class=\\\"MultiMediaCaption\\\"><a name=\\\"fig2\\\"></a><span class=\\\"Bold\\\">Figure 2. Mean HbA1c (%) Over Time - Baseline to Week 40</span></p><div class=\\\"Figure\\\"><a name=\\\"f03\\\"></a><img alt=\\\"Figure 2\\n\\\" src=\\\"moun-uspi-f2-v1.jpg\\\"/></div><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"15.599%\\\"/><col align=\\\"left\\\" width=\\\"5.053%\\\"/><col align=\\\"left\\\" width=\\\"6.538%\\\"/><col align=\\\"left\\\" width=\\\"6.538%\\\"/><col align=\\\"left\\\" width=\\\"6.538%\\\"/><col align=\\\"left\\\" width=\\\"6.538%\\\"/><col align=\\\"left\\\" width=\\\"6.538%\\\"/><col align=\\\"left\\\" width=\\\"6.538%\\\"/><col align=\\\"left\\\" width=\\\"6.538%\\\"/><col align=\\\"left\\\" width=\\\"11.276%\\\"/><col align=\\\"left\\\" width=\\\"6.615%\\\"/><col align=\\\"left\\\" width=\\\"5.784%\\\"/><col align=\\\"left\\\" width=\\\"9.907%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"right\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Number of patients</span></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"right\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO 5mg</span></td><td align=\\\"right\\\" valign=\\\"top\\\">470</td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\">451</td><td align=\\\"right\\\" valign=\\\"top\\\">470</td><td align=\\\"right\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"right\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO 10mg</span></td><td align=\\\"right\\\" valign=\\\"top\\\">469</td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\">445</td><td align=\\\"right\\\" valign=\\\"top\\\">469</td><td align=\\\"right\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"right\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO 15mg</span></td><td align=\\\"right\\\" valign=\\\"top\\\">469</td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\">447</td><td align=\\\"right\\\" valign=\\\"top\\\">469</td><td align=\\\"right\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"right\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Semaglutide 1mg</span></td><td align=\\\"right\\\" valign=\\\"top\\\">468</td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\"></td><td align=\\\"right\\\" valign=\\\"top\\\">443</td><td align=\\\"right\\\" valign=\\\"top\\\">468</td><td align=\\\"right\\\" valign=\\\"top\\\"></td></tr></tbody></table><p>Note: Displayed results are from modified Intent-to-Treat Full Analysis Set. (1) Observed mean value from Week 0 to Week 40, and (2) least-squares mean ± standard error at Week 40 multiple imputation (MI).</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s78\\\"></a><a name=\\\"section-13.3.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Add-on to metformin with or without SGLT2 inhibitor</span></p><p>SURPASS-3 (NCT03882970) was a 52-week open-label trial that randomized 1444 adult patients with type 2 diabetes mellitus with inadequate glycemic control on stable doses of metformin with or without SGLT2 inhibitor to the addition of MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin degludec 100 units/mL once daily. In this trial, 32% of patients were on SGLT2 inhibitor. Insulin degludec was initiated at 10 units once daily and adjusted weekly throughout the trial using a treat-to-target algorithm based on self-measured fasting blood glucose values. At Week 52, 26% of patients randomized to insulin degludec achieved the fasting serum glucose target of &lt;90 mg/dL, and the mean daily insulin degludec dose was 49 U (0.5 U per kilogram).</p><p>Patients had a mean age of 57 years, and 56% were men. The mean duration of type 2 diabetes mellitus was 8.4 years, and the mean baseline BMI was 34 kg/m<span class=\\\"Sup\\\">2</span>. Overall, 91% were White, 3% were Black or African American, and 5% were Asian; 29% identified as Hispanic or Latino ethnicity.</p><p>Treatment with MOUNJARO 10 mg and 15 mg once weekly for 52 weeks resulted in a statistically significant reduction in HbA1c compared with daily insulin degludec (see <a href=\\\"#t5\\\">Table 5</a>).</p><a name=\\\"t5\\\"></a><table width=\\\"100%\\\"><caption><span>Table 5: Results at Week 52 in a Trial of MOUNJARO versus Insulin Degludec in Adult Patients with Type 2 Diabetes Mellitus Added to Metformin with or without SGLT2 Inhibitor</span></caption><col align=\\\"left\\\" width=\\\"40.528%\\\"/><col align=\\\"left\\\" width=\\\"14.883%\\\"/><col align=\\\"left\\\" width=\\\"14.863%\\\"/><col align=\\\"left\\\" width=\\\"14.863%\\\"/><col align=\\\"left\\\" width=\\\"14.863%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 1%,1%, 1%, and 2% of patients randomized to insulin degludec, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 52 the HbA1c endpoint was missing for 9%, 6%, 10%, and 5% of patients randomized to insulin degludec, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 52 data were imputed using multiple imputation with retrieved dropout.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> p&lt;0.001 (two-sided) for superiority vs. insulin degludec, adjusted for multiplicity.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">d</span> Analyzed using logistic regression adjusted for baseline value and other stratification factors.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Insulin Degludec</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO<br/>5 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO<br/>10 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO<br/>15 mg</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Modified Intent-to-Treat (mITT)<span class=\\\"Sup\\\">a</span> Population (N)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">359</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">358</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">360</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">358</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">HbA1c (%)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline (mean)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8.2</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Change at Week 52<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-1.9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-2.1</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Difference from insulin degludec<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">--</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.6<span class=\\\"Sup\\\">c</span><br/>(-0.7, -0.5)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.8<span class=\\\"Sup\\\">c</span><br/>(-0.9, -0.6)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-0.9<span class=\\\"Sup\\\">c</span><br/>(-1.0, -0.7)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Patients (%) achieving HbA1c &lt;7%<span class=\\\"Sup\\\">d</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">58</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">79<span class=\\\"Sup\\\">c</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">82<span class=\\\"Sup\\\">c</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">83<span class=\\\"Sup\\\">c</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Fasting Serum Glucose (mg/dL)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline (mean)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">167</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">172</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">170</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">168</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Change at Week 52<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-51</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-47</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-50</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-54</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Body Weight (kg)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline (mean)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">94.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">94.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">93.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">94.9</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Change at Week 52<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1.9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-7.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-9.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-11.3</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Difference from insulin degludec<span class=\\\"Sup\\\">b</span> (95% CI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">--</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-8.9<span class=\\\"Sup\\\">c</span><br/>(-10.0, -7.8)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-11.5<span class=\\\"Sup\\\">c</span><br/>(-12.6, -10.4)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">-13.2<span class=\\\"Sup\\\">c</span><br/>(-14.3, -12.1)</td></tr></tbody></table></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s79\\\"></a><a name=\\\"section-13.3.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea or SGLT-2 inhibitor)</span></p><p>SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%).</p><p>Patients had a mean age of 64 years, and 63% were men. The mean duration of type 2 diabetes mellitus was 11.8 years, and the mean baseline BMI was 33 kg/m<span class=\\\"Sup\\\">2</span>. Overall, 82% were White, 4% were Black or African American, and 4% were Asian; 48% identified as Hispanic or Latino ethnicity. Across all treatment groups, 87% had a history of cardiovascular disease. At baseline, eGFR was ≥90 mL/min/1.73 m<span class=\\\"Sup\\\">2</span> in 43%, 60 to 90 mL/min/1.73 m<span class=\\\"Sup\\\">2</span> in 40%, 45 to 60 mL/min/1.73 m<span class=\\\"Sup\\\">2</span> in 10%, and 30 to 45 mL/min/1.73 m<span class=\\\"Sup\\\">2</span> in 6% of patients.</p><p>Insulin glargine was initiated at 10 U once daily and adjusted weekly throughout the trial using a treat-to-target algorithm based on self-measured fasting blood glucose values. At Week 52, 30% of patients randomized to insulin glargine achieved the fasting serum glucose target of &lt;100 mg/dL, and the mean daily insulin glargine dose was 44 U (0.5 U per kilogram).</p><p>Treatment with MOUNJARO 10 mg and 15 mg once weekly for 52 weeks resulted in a statistically significant reduction in HbA1c compared with insulin glargine once daily (see <a href=\\\"#t6\\\">Table 6</a>).</p><a name=\\\"t6\\\"></a><table width=\\\"100%\\\"><caption><span>Table 6: Results at Week 52 in a Trial of MOUNJARO versus Insulin Glargine in Adult Patients with Type 2 Diabetes Mellitus Added to Metformin and/or Sulfonylurea and/or SGLT2 Inhibitor</span></caption><col align=\\\"left\\\" width=\\\"43.691%\\\"/><col align=\\\"left\\\" width=\\\"13.777%\\\"/><col align=\\\"left\\\" width=\\\"14.177%\\\"/><col align=\\\"left\\\" width=\\\"14.177%\\\"/><col align=\\\"left\\\" width=\\\"14.177%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 1%, 0%, 0%, and 1% of patients randomized to insulin glargine, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 52 the HbA1c endpoint was missing for 9%, 9%, 6%, and 4% of patients randomized to insulin glargine, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 52 data were imputed using multiple imputation with retrieved dropout.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> p&lt;0.001 (two-sided) for superiority vs. insulin glargine, adjusted for multiplicity.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">d</span> Analyzed using logistic regression adjusted for baseline value and other stratification factors.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Insulin Glargine</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO<br/>5 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO<br/>10 mg</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">MOUNJARO<br/>15 mg</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Modified Intent-to-Treat (mITT) Population (N)<span class=\\\"Sup\\\">a</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">998</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">328</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" "